Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Akinchan Bhardwaj/LinkedIn
Mar 19, 2026, 17:14

Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs

Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Lana A. Castellucci published in NEJM, adding:

“Two of the most commonly used anticoagulants in the world… but are they really equivalent?

For years, clinicians have treated apixaban and rivaroxaban as largely interchangeable for venous thromboembolism.

A new randomized trial published in NEJM challenges that assumption.

In the COBRRA trial, more than 2700 patients with acute VTE were randomized to apixaban or rivaroxaban. Striking results!

Clinically relevant bleeding

  • Apixaban: 3.3%
  • Rivaroxaban: 7.1%

That is about a 54% relative reduction in bleeding risk.

Importantly, this difference appeared within the first 3 months, the highest-risk phase of anticoagulation therapy.

Why this matters clinically?

  • Anticoagulation decisions are rarely about efficacy alone.
  • They are about balancing thrombosis prevention with bleeding risk.
  • If two agents prevent clots similarly but one carries substantially less bleeding, that changes real-world prescribing decisions.

For clinicians managing:

  • Pulmonary embolism
  • Proximal DVT
  • Early anticoagulation after diagnosis

These data may influence which DOAC becomes the default choice.

Bigger picture:

We often assume drugs within the same class behave the same.

But trial-level comparisons show us that pharmacology still matters.

Small differences in mechanism, dosing schedules, and pharmacokinetics can translate into meaningful differences for patients.

Curious how others are thinking about this.

Would this change your first-line DOAC choice in acute VTE?”

Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger

Read the Full Article on NEJM

Akinchan Bhardwaj

More posts featuring Akinchan Bhardwaj on Hemostasis Today.

Abbey Willcox Akinchan Bhardwaj Alejandro Lazo-Langner Anticoagulation Apixaban Benoit Côté Bleeding Risk Clive Kearon COBRRA Trial Deepa Suryanarayan DOAC Erik Yeo Erin Thomas Etimbuk Umana Fionnuala Ní Áinle Genevieve Le Templier Gregoire Le Gal Health Helen J. Crowther Hematology Hemostasis Hemostasis News Hemostasis Today Huyen A. Tran James Douketis Jean-Philippe Galanaud Kerstin de Wit Lana A. Castellucci Lisa Baumann Kreuziger Marc Blondon Marc Rodger Medicine Michael J. Kovacs NEJM New England Journal of Medicine Peter Greenstreet Ritam Prasad Rivaroxaban Sam Schulman Stefano Barco Sudeep Shivakumar Susan Kahn Susan Solymoss Tim Ramsay Tobias Tritschler Tony Wan Vivien M. Chen
NewsFeed